Placebo Cap

DRUG7 trials

Sponsors

China Medical University Hospital

Conditions

Bipolar I DisorderMajor Depressive DisorderProdromal SchizophreniaSchizophrenia

Phase 2

NMDA Modulation in Major Depressive Disorder

RecruitingNCT04637620

China Medical University HospitalMajor Depressive Disorder

Start: 2017-06-01End: 2026-12-31Target: 90Updated: 2025-02-19

Monotherapy of an NMDA Enhancer for Schizophrenia

RecruitingNCT04745143

China Medical University HospitalSchizophrenia

Start: 2018-01-01End: 2027-12-01Target: 80Updated: 2026-03-24

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

RecruitingNCT05052853

China Medical University HospitalProdromal Schizophrenia

Start: 2021-11-01End: 2026-12-01Target: 48Updated: 2026-03-24

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

RecruitingNCT05136755

China Medical University HospitalMajor Depressive Disorder

Start: 2022-01-25End: 2026-12-31Target: 50Updated: 2025-02-19

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

RecruitingNCT05977023

China Medical University HospitalBipolar I Disorder

Start: 2023-10-04End: 2027-12-31Target: 90Updated: 2025-02-19

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

RecruitingNCT06021197

China Medical University HospitalSchizophrenia

Start: 2023-10-12End: 2028-03-31Target: 90Updated: 2025-02-19

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

RecruitingNCT07122895

China Medical University HospitalSchizophrenia

Start: 2025-09-16End: 2030-03-31Target: 90Updated: 2025-09-17